These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9111826)

  • 41. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
    Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
    J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclosporine as maintenance therapy in patients with severe psoriasis.
    Shupack J; Abel E; Bauer E; Brown M; Drake L; Freinkel R; Guzzo C; Koo J; Levine N; Lowe N; McDonald C; Margolis D; Stiller M; Wintroub B; Bainbridge C; Evans S; Hilss S; Mietlowski W; Winslow C; Birnbaum JE
    J Am Acad Dermatol; 1997 Mar; 36(3 Pt 1):423-32. PubMed ID: 9091474
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined treatment with low-dose cyclosporine and calcipotriol/betamethasone dipropionate ointment for moderate-to-severe plaque psoriasis: a randomized controlled open-label study.
    Vena GA; Galluccio A; Pezza M; Vestita M; Cassano N
    J Dermatolog Treat; 2012 Aug; 23(4):255-60. PubMed ID: 21756153
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship between lymphocyte cyclosporin sensitivity and clinical progress of psoriasis.
    Umezawa Y; Oh-i T; Koga M
    J Dermatol Sci; 2001 Jun; 26(2):94-9. PubMed ID: 11378324
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of oral cyclosporin A (CyA; Sandimmun) for long-term treatment of chronic severe plaque psoriasis.
    Laburte C; Grossman R; Abi-Rached J; Abeywickrama KH; Dubertret L
    Br J Dermatol; 1994 Mar; 130(3):366-75. PubMed ID: 8148280
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
    Krueger GG; Papp KA; Stough DB; Loven KH; Gulliver WP; Ellis CN;
    J Am Acad Dermatol; 2002 Dec; 47(6):821-33. PubMed ID: 12451365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study.
    Papp K; Bissonnette R; Rosoph L; Wasel N; Lynde CW; Searles G; Shear NH; Huizinga RB; Maksymowych WP
    Lancet; 2008 Apr; 371(9621):1337-42. PubMed ID: 18424323
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
    Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
    Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and tolerability of multiple-dose SDZ IMM 125 in patients with severe psoriasis.
    Witkamp L; Zonneveld IM; Jung EG; Schopf RE; Christophers E; Grossman R; Meffert H; Belaich S; Mahrle G; Van Joost T
    Br J Dermatol; 1995 Jul; 133(1):95-103. PubMed ID: 7669649
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis.
    Ameen M; Smith HR; Barker JN
    Clin Exp Dermatol; 2001 Sep; 26(6):480-3. PubMed ID: 11678869
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity.
    van de Kerkhof PC; Wasel N; Kragballe K; Cambazard F; Murray S
    Dermatology; 2005; 210(4):294-9. PubMed ID: 15942215
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cyclosporin trough levels: is monitoring necessary during short-term treatment in psoriasis? A systematic review and clinical data on trough levels.
    Heydendael VM; Spuls PI; Ten Berge IJ; Opmeer BC; Bos JD; de Rie MA
    Br J Dermatol; 2002 Jul; 147(1):122-9. PubMed ID: 12100194
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the TĪ±ranta Plastic Study Group.
    Cassano N; Loconsole F; Miracapillo A; Travaglini M; Digiuseppe MD; Congedo M; Galluccio A; Buquicchio R; Mastrandrea V; Filieri M; Raho G; Pezza M; Vena GA
    Int J Immunopathol Pharmacol; 2010; 23(3):797-802. PubMed ID: 20943050
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cyclosporin in psoriasis: how?
    Feldman SR; Garton R
    J Eur Acad Dermatol Venereol; 2004 May; 18(3):250-3. PubMed ID: 15096128
    [No Abstract]   [Full Text] [Related]  

  • 58. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3.
    Egeberg A; Wu JJ; Korman N; Solomon JA; Goldblum O; Zhao F; Mallbris L
    J Am Acad Dermatol; 2018 Jul; 79(1):104-109.e8. PubMed ID: 29548945
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Algorithm to select optimal systemic anti-psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis.
    Bae SH; Yun SJ; Lee JB; Kim SJ; Won YH; Lee SC
    J Dermatol; 2016 Jun; 43(6):643-9. PubMed ID: 26598783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.